Lacking in Trials

May 1, 2003
Barbara J. Rutledge, PhD

San Francisco - Despite the importance of knowing which of the numerous treatment modalities should be used as first-line treatment for basal cell carcinoma (BCC), there is a severe lack of well-designed, randomized, controlled trials to evaluate the different treatment options, according to Jan Bong, M.B., C.H.B., M.R.C.P., of Queen's Medical Centre, University of Nottingham.